Indivior PLC

INVVY

$21.85

Updated: 22/09/2026, 20:26:07

Market Cap

$3.01B

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

No historical data available

Company Profile

Indivior PLC, encompassing its various subsidiaries, is a pharmaceutical firm dedicated to the research, production, and global commercialization of prescription medications. These therapies primarily utilize buprenorphine to treat opioid dependence and associated medical conditions. The company's development pipeline is actively exploring novel treatments for opioid use disorder (OUD) and schizophrenia. Its current portfolio features the SUBLOCADE subcutaneous injection, along with sublingual formulations like SUBOXONE film, SUBOXONE tablets, and SUBUTEX tablets. Additionally, Indivior sells established products such as Temgesic, Burpex, and Buprenex. With operations spanning approximately 40 countries worldwide, the company also maintains a research collaboration agreement with Addex Therapeutics Ltd. Indivior PLC was founded in 2014 and is headquartered in North Chesterfield, Virginia.

USD

OTC

CEO: Mark Crossley

Employees: 1,000

https://www.indivior.com

Asset Summaries

Latest generated summaries for INVVY

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for INVVY.

Share price: $21.85
Market cap: $3.01B
Exchange: OTC
Currency: USD
CEO: Mark Crossley
Employees: 1,000
IPO date: 09/06/2015
Beta: -0.059574
Last dividend: $0.00
Day range: $21.85 – $21.85
52-week range: $14.76 – $75.65
1-day performance: 0.00%
1-year performance: 48.00%
Current drawdown (1Y): -71.12%
CIK: N/A
CUSIP: N/A
ISIN: N/A
Created: 07/12/2025, 04:45:02
Last update: 22/09/2026, 20:26:07

Track Indivior PLC with an AI analyst

See which prediction-market events move INVVY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to INVVY from your Railway `news_articles` table.

Is Indivior Stock a Buy After Higher 2026 Guidance?

Zacks Investment Research • STOCK • 12/06/2026, 13:16:12

Indivior Announces $175 Million Accelerated Share Repurchase

GlobeNewsWire • STOCK • 04/05/2026, 09:00:00

Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 30/04/2026, 22:21:33

Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates

Zacks Investment Research • STOCK • 30/04/2026, 11:35:26

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

GlobeNewsWire • STOCK • 09/04/2026, 09:00:00

Indivior: Still Attractive After FY25 Earnings Beat

Seeking Alpha • STOCK • 30/03/2026, 15:23:36

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

GlobeNewsWire • STOCK • 12/03/2026, 21:30:00

Indivior Announces Proposed Convertible Senior Notes Offering

GlobeNewsWire • STOCK • 12/03/2026, 08:00:00